Skip to content

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06776588
Enrollment
200
Registered
2025-01-15
Start date
2025-01-15
Completion date
2028-01-15
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.

Detailed description

Combining AI and fragmentomics technology, this study enrolled 200 patients with ground-glass lung cancer for comprehensive evaluation. By collecting detailed characteristic data of ground-glass lung cancer, including nodule diameter, average CT value, solid component ratio (CTR), nodule morphology and other related signs, CT imaging and AI technology, and fragmentomics technology were used for comprehensive analysis to form a set of joint strategies to efficiently screen and diagnose patients with early lung cancer. Microwave ablation is used to treat lung nodules, and intraoperative rapid pathology technology is used to determine the nature of the punctured tissue and the degree of ablation (observing pathological changes in the lesion area, including cancer cell death and fibrosis of the lesion tissue), determine whether the lesion has been completely ablated, or whether there are residual active cancer cells, and then explore the optimal ablation time and ablation power. Finally, long-term follow-up of patients after microwave ablation, including collection of intraoperative/postoperative complication data, regular CT review, evaluation of treatment effect, monitoring for recurrence, and improving individualized treatment plans for patients.

Interventions

PROCEDUREMicrowave ablation combined with biopsy

CT thin-layer scanning 3D reconstruction is used, and AI and fragment omics technology are used to evaluate the risk of malignant transformation of pulmonary nodules. Microwave ablation of pulmonary nodules is combined with intraoperative rapid pathology technology to determine the nature of punctured tissue and the degree of ablation, and to explore the optimal ablation time and ablation power.

Sponsors

Beidahuang Industry Group General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≤ 75 years; 2. GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm; 3. Refusing radical surgery or being unable to tolerate surgical treatment; 4. Normal coagulation function, platelet count ≥ 60 × 109 /L; 5. ECOG score ≤ 2 points;

Exclusion criteria

1. Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm 2. Platelets \<50×109 /L 3. Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term 4. Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension 5. Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation 6. Patients with severe heart, liver, kidney and brain dysfunction 7. Patients with severe anemia, dehydration and cachexia that cannot be corrected or improved in the short term 8. Patients with an estimated survival period of less than 6 months

Design outcomes

Primary

MeasureTime frameDescription
Local contral rateup to 36 monthsLCR is the rate of CR, PR plus SD
Recurrence-free survivalup to 36 monthsIt estimates the recurrence-free rate of patients who have already survived, with no history of metastasis, a certain period of time.
Overall Survivalup to 36 monthsDefined as the time from randomization to death from any cause.

Secondary

MeasureTime frameDescription
Detection rateup to 36 monthsThe detection rate of early lung cancer was calculated

Other

MeasureTime frameDescription
To explore the optimal ablation timeup to 36 monthsTo explore the optimal ablation time
To explore the optimal power selectionup to 36 monthsTo explore the optimal power selection

Countries

China

Contacts

Primary ContactMingyang Liu
redrumff@163.com86+451 5519 7877

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026